India's first H5N1 bird flu vaccine for poultry launched by Shivraj Singh Chouhan
Synopsis
Key Takeaways
Union Minister of Agriculture and Farmers Welfare Shivraj Singh Chouhan on Friday, 20 November 2026, dedicated India's first indigenous inactivated H5N1 Highly Pathogenic Avian Influenza (HPAI) vaccine for poultry to the nation — a landmark moment for the country's biosecurity and agriculture sectors. Developed by the Bhopal-based ICAR-National Institute of High Security Animal Diseases (ICAR-NIHSAD), the vaccine was unveiled at the institute and directly addresses the circulating H5N1 Clade 2.3.2.1a strain — against which no commercial vaccine had previously existed in India.
What Makes This Vaccine a Breakthrough
Until now, India's poultry sector had no strain-specific commercial protection against the H5N1 Clade 2.3.2.1a variant responsible for most domestic outbreaks in chickens. ICAR-NIHSAD's indigenous inactivated vaccine fills this critical gap, targeting the circulating strain directly rather than relying on broader, less-effective formulations. Recent virological studies indicate this clade has also been detected in mammals, alongside three reported human cases, adding urgency to the vaccine's deployment.
The unveiling marks a significant step in indigenising India's veterinary pharmaceutical capabilities — reducing dependence on imports and enabling faster outbreak response at scale.
The Scale of Bird Flu's Threat to India
India has recorded more than 500 outbreaks of avian influenza involving the H5N1 and H5N8 subtypes since the first confirmed domestic case in 2006. The economic toll has been severe: the 2006 outbreak alone inflicted estimated direct and indirect losses of ₹2,200 crore to ₹3,000 crore, while a separate outbreak in Manipur caused losses equivalent to 0.5% of the state's GDP.
Official estimates warn that a major outbreak could shave 1.5% off India's GDP growth and put more than 20% of the national poultry population at risk. Beyond economics, outbreaks trigger mass culling, international trade bans, and sharp spikes in poultry product prices — all of which hit farmers and consumers hardest.
Public Health Dimension
H5N1 is not merely an agricultural concern. According to the World Health Organization (WHO), 1,003 human cases of H5N1 avian influenza — resulting in 479 deaths — have been reported across 25 countries, including India, since 2003. The virus's documented ability to infect mammals and, in rare instances, humans means that protecting poultry populations is also a first line of defence for public health.
By limiting viral transmission from chickens to other animals and potentially to humans, the new vaccine is expected to reduce zoonotic risk — a priority the government and health authorities have emphasised in the context of pandemic preparedness.
What Happens Next
With the vaccine now formally dedicated to the nation, attention shifts to its rollout across vulnerable poultry populations, particularly in states with histories of repeated outbreaks. Industry bodies and state animal husbandry departments are expected to coordinate deployment timelines. The development also positions ICAR-NIHSAD as a key node in India's animal disease research infrastructure, with potential for the institute to extend its work to other high-pathogenicity strains in the future.